Theta-Defensin Formulation With Acidic pH for Low-Viscosity Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating chronic inflammation with θ-defensins suffer from low bioavailability, high viscosity leading to injection site reactions, and require high doses to achieve therapeutic efficacy, limiting their use in human therapy.
Innovation Solution
Formulations of θ-defensins in an aqueous solution with 0.5% to 1.5% propylene glycol and a pH of 5.0 to 7.0, which enhance bioavailability and reduce viscosity, allowing for subcutaneous administration with reduced injection site reactions and increased pharmacodynamic effect up to 40-fold.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If θ-defensins are administered in conventional formulations, then therapeutic efficacy can be achieved, but bioavailability is low and high doses are required
Solution Approach 1:
The patent changes the pH parameter of the formulation from conventional neutral pH to acidic pH (5.0-7.0), and incorporates propylene glycol (0.5%-1.5%) as a formulation modifier. These parameter changes result in a 10- to 40-fold increase in pharmacologic potency, allowing significantly lower doses to achieve the same therapeutic efficacy.
2Productivity
If θ-defensins are formulated with high concentration, then dosage efficiency improves, but viscosity increases causing injection site reactions
Solution Approach 1:
The patent applies parameter changes by adjusting the pH to acidic range (5.0-7.0) and adding propylene glycol (0.5%-1.5%), which reduces the viscosity of concentrated θ-defensin solutions. This enables formulation of high-concentration preparations that remain injectable and do not cause injection site reactions, thereby improving dosage efficiency while eliminating harmful effects.
3Adaptability or versatility
If θ-defensins are administered systemically, then therapeutic coverage is improved, but tolerability decreases due to adverse effects
Solution Approach 1:
The patent employs parameter changes by formulating θ-defensins in an acidic pH environment (5.0-7.0) with propylene glycol (0.5%-1.5%). This formulation approach enhances systemic tolerability by reducing adverse effects, while maintaining or improving therapeutic coverage. The modified formulation parameters allow for effective systemic administration with minimal toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide improved pharmacologic potency and reduced viscosity, enabling effective treatment of chronic inflammatory conditions with lower doses and minimal adverse effects, facilitating scalable sterilization by filtration.
Implementation Method 1
Formulations of θ-defensins in an aqueous solution with 0.5% to 1.5% propylene glycol and a pH of 5.0 to 7.0, which enhance bioavailability and reduce viscosity
Implementation Method 2
Formulations of θ-defensins in an aqueous solution with 0.5% to 1.5% propylene glycol and a pH of 5.0 to 7.0, which enhance bioavailability
Data Source
AI summary
Compositions are provided for formulations of θ-defensin and/or a θ-defensin analog that are highly suitable for parenteral administration. Such formulations provide the θ-defensin and/or a θ-defensin analog in a slightly acidic buffer that includes propylene glycol. Surprisingly, Inventors have found that such formulation increase bioavailability of a θ-defensin and/or a θ-defensin analog so provided by at least a factor of 10 relative to conventional isotonic saline solutions, and that such formulations dramatically improved bioavailability in human subjects relative to animal models. Inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, reducing injection volume permitting sterilization by simple filtration.